Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Dihydromyricetin has demonstrated promising effects in glycemic control, insulin sensitivity and insulin secretion, that above mentioned findings show that dihydromyricetin has an excellent potential effect in the treatment of type 2 diabetes mellitus patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Treatments: Insulin; Metformin

Criteria

Inclusion Criteria:

• Patients both sexes

• Age between 30 and 60 years

• Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with one of the following criteria (fasting blood glucose levels >126 mg/dL; postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose >200 mg/dl; or glycosylated hemoglobin between >6.5%)

• Informed consent signed

Exclusion Criteria:

• Women with confirmed or suspected pregnancy, or under lactation and/or puerperium

• Previous treatment for glucose

• Fasting glucose ≥250 mg/dL

• Body Mass Index ≥34.9 kg/m2

• Known uncontrolled renal, hepatic, heart or thyroid diseased

• Hypersensibility to ingredients of intervention

• Triglycerides ≥500 mg/dL

• Total cholesterol ≥240 mg/dL

• Blood Pressure ≥140/90 mmHg